Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA approved Eli Lilly and Co's treatment for advanced gastric cancer after prior chemotherapy


Monday, 21 Apr 2014 10:00pm EDT 

Eli Lilly and Co:Says U.S. Food and Drug Administration approved CYRAMZA (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction.With this approval, CYRAMZA becomes the first FDA-approved treatment for patients in this setting. 

Company Quote

52.0
0.72 +1.40%
24 Oct 2014